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Background: The pathophysiology of type2 diabetes involves both insulin resistance and poor beta cell function.
Studies have been done in several populations to assess the relative importance of these mechanisms in individual
patients. In our environment studies to assess beta cell function have been done with glucagon stimulation or an
oral glucose tolerance test. This study was done to assess the response of the beta cell to a standardized mixed
meal and its relationship with glycaemic control in patients with type2 diabetes.
Methods: Ninety patients with type 2 diabetes were recruited into the study. Weight, height, body mass index and
waist circumference were measured. Blood samples were analysed for fasting plasma glucose (FPG) and fasting C
peptide (FCP) and glycated haemoglobin (HbA1c). Patients were given their usual drugs for management of their
diabetes and then served with a standard meal calculated to contain 50 g of carbohydrate, made up of 53 %
carbohydrate, 17 % of protein and 30 % of lipids, providing 500 kcal. Blood samples 2 hours after the start of the
meal were analysed for postprandial glucose (PPG) and postprandial C peptide (PCP). Fasting (M0) and postprandial
beta cell responsiveness (M1) were calculated.
Results: The mean FPG and PPG were 7.51+/− 3.39 mmol/l and 11.02+/−4.03 mmol/l respectively while the mean
glycated haemoglobin (HbA1c) was 9.0+/−2.5 %. The mean fasting C peptide was 1.44+/−1.80ug/ml. Many of the
patients (56.7 %) had low FCP levels. The mean postprandial C peptide was 4.0+/−2.8 ng/ml. There were significant
correlations between M1, HbA1c and PPG (p = 0.015, 0.024, 0.001 respectively) and also between M0, HbA1c, PPG
and FPG (p = 0.001, 0.002, 0.001). HbA1c decreased across increasing tertiles of M0 (p< 0.001) and also M1
(p = 0.002). In step-wise linear regression analysis, M0 and M1 significantly predicted HbA1c.
Conclusions: Many of the patients had low C peptide levels with poor beta cell response to the meal. The patients
had poor glycaemic control and poor beta cell function. Both fasting and postprandial beta cell responsiveness
were significant determinants of blood glucose and glycated haemoglobin levels. It is likely that putting these
patients on insulin may have led to better glycaemic control in them.
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In patients with type2 diabetes, poor beta cell function
and insulin resistance are the major mechanisms that
lead to chronic hyperglycaemia [1]. In the UKPDS, it
was demonstrated that at diagnosis beta cell function
was reduced by up to 50 % and there was subsequent
further deterioration regardless of therapy [2]. It has
been postulated that beta cell exhaustion, reduction in
beta cell mass and desensitization of beta cells result in* Correspondence: ekeneyoung@yahoo.com
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reproduction in any medium, provided the orbeta cell dysfunction [3]. Abnormalities of insulin secre-
tion in persons with overt type 2 diabetes include
reduced or absent first-phase responses to intravenous
glucose, delayed and blunted secretory responses to in-
gestion of a mixed meal, alteration in rapid pulses and
ultradian oscillation of insulin secretion and an increase
in the plasma concentration of pro-insulin [4]. Poor beta
cell function occurs to varying degrees and commonly
manifests as a poor first phase response to a glucose
load [5]. Though beta cell responsiveness has been
shown to decrease with increasing duration of diabetes,
the rate of deterioration differs in patients. Patients whoLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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glycaemic control at an earlier time from onset of dia-
betes than others; however beta cell function is not rou-
tinely assessed in type2 diabetic patients at diagnosis.
Various models have been used to assess the response
of the beta cell to a glucose load, a mixed meal or gluca-
gon stimulation [6]. The use of a meal tolerance test to
assess beta cell function is regarded as a more physio-
logical test than the use of a glucose load or glucagon
stimulation as it has the benefit of evaluating a typical
pancreatic postprandial exposure to glucose and other
nutrients and gut and vagal hormones [7].
Some studies have suggested that there are ethnic dif-
ferences in the degree of beta cell depletion[8,9]. Black
South African type 2 diabetic subjects have been found
to be more likely than their African-American counter-
parts to develop depletion of beta-cell function [10].
Basal and stimulated C-peptide levels were also found to
be lower in black South Africans compared to South Af-
rican Indians and whites in both diabetic and non-
diabetic populations[10].
The aim of this study was to estimate beta cell re-
sponse to a standardised meal in Nigerian patients with
type2 diabetes and also determine the relationship be-
tween their beta cell function and glycaemic control.
Other studies on beta cell function done in this environ-
ment have been with the use of oral glucose [9], or glu-
cagon stimulation [11].
Methods
The study was conducted in the diabetes out-patient
clinic of the University of Port Harcourt Teaching Hos-
pital, Port Harcourt in the oil-rich Niger-Delta region of
Nigeria. Ethical approval for the study was obtained
from the hospital ethics committee prior to commence-
ment of the study.
Ninety patients managed for type 2 diabetes who gave
written consent were recruited consecutively as they
attended the diabetic clinic for follow-up. The patients
were assessed with questionnaires to obtain demo-
graphic data and those who met the inclusion criteria
for the study were asked to report early in the morning
on the day of the test after an overnight fast of 8 to
10hours.
Inclusion criteria:
1. Patients earlier classified as having type2 diabetes
and on a stable treatment regimen in the last
3 months. Patients were classified as type2 diabetic
using clinical criteria. Patients who were above
40 years at diagnosis, did not require insulin for
survival, had no features suggestive of secondary
diabetes and were not on steroids, oral contraceptivepills or other diabetogenic drugs were presumed to
have type2 diabetes and recruited into the study.
2. Patients without any features of metabolic
decompensation (i.e evidence of ketosis,
hypoglycaemia, advanced heart failure or uraemia) at
the time of the test.
3. Patients who gave informed written consent.
Exclusion criteria:
1. Patients with type1 diabetes. These were classified
clinically as antibody testing was unavailable.
Patients who were less than 40 years at diagnosis
and were dependent on insulin for survival were
classified as type1 diabetic patients.
On the day of the test, the weight of the patients was
measured using a standard scale and recorded to the
nearest kg. Height was measured using a stadiometer
without shoes or stockings on and recorded to the near-
est 0.01 m. Body mass index was calculated with the
standard formula; Weight(kg)/height 2(m2). Waist cir-
cumference was measured with a flexible tape with the
patient standing erect in light clothing at a point midway
between the iliac crest and the lower margin of the rib
cage. Blood pressure was measured with a standard mer-
cury sphygmomanometer and the average of two read-
ings taken five minutes apart was recorded.
Fasting venous samples were collected from a periph-
eral vein for the assessment of fasting plasma glucose
and fasting C peptide. After the initial sample, the
patients were given a pre-packaged meal which had been
formulated to contain 50 g of carbohydrate and 500 kcal
and their medications were taken as usual. The mixed
meal was made up of 53 % carbohydrate, 17 % of protein
and 30 % of lipids. It consisted of a sandwich made with
whole wheat bread, fried tomatoes, lettuce and onions
and a cup of tea to which had been added 1 % fat milk.
The meal was formulated by the hospital dietician.
Patients were asked to consume the meal within 15
minutes.
Samples were collected and analysed for glucose and
C peptide two hours after the start of the meal. Blood
glucose was analysed using the glucose oxidase method
while HBA1c was analysed with an in2it machine from
Bio Rad Laboratories which is DCCT calibrated and uses
the Boronate affinity method. C peptide was analysed
using an ELISA based kit (Diagnostic Automation Inc.
USA).
The modified formula of Hovorka [12] was used to
calculate fasting beta cell responsiveness(M0) and also
postprandial beta cell responsiveness(M1). Fasting beta
cell responsiveness was taken to be the ability of fasting
glucose to stimulate insulin production by the beta cell,
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as the ability of postprandial glucose to stimulate the
beta cell.
M0 ¼ 100 FC peptide μg=lð Þ= FPG mg=dlð Þ:
M1 ¼ 100½PP 2h C peptide μg=lð Þ
 FC peptide μg=lð Þ= ½PPG2h mg=dlð Þ
 FPG mg=dlð Þ:
Statistical analysis
Results were analysed with Statistical package for social
sciences (SPSS v15). Continuous variables were pre-
sented as means ± S.D and categorical variables
expressed as frequencies. Chi square test was used to
compare categorical variables while the difference be-
tween continuous variables was analysed with the stu-
dents t test or ANOVA. C peptide values, M0 and M1
were log transformed to accommodate the skewing of
the variables. In addition, the patients were divided
according to their tertiles of M0 and M1 and various
clinical characteristics were compared among the three
groups. Correlations between duration of diabetes, age,
FPG, PPG, HBA1c, M0 and M1 were performed using
Pearsons correlation coefficient. Stepwise multiple re-
gression analysis was performed with HbA1c as a
dependent variable while variables of age, duration of
diabetes, gender, M0 and M1were analyzed as independ-




The mean age and duration of diabetes were
57.7 ± 10.8 years and 6.77 ± 6.53 years respectively. Oral
drugs only were used in 71.1 % of the patients, and this
consisted of Metformin alone in 11.1 %, Metformin and
Sulphonylurea in 55.6 %, and Sulphonylurea alone in
4.4 %. Insulin (either alone or in combination with met-
formin) was used in 22.3 % of the patients and only
6.6 % were on diet and lifestyle measures only.
The mean BMI of the patients was 27.54 ± 6.01 kg/m2
. Obesity (BMI> 30 kg/m2) was present in 16.6 % of the
patients while 38.6 % of them were overweight
(BMI> 25 kg/m2). Hypertension was present in 45.6 %
of the patients.
Glycaemic Control
The mean fasting plasma glucose and 2hour postpran-
dial glucose were 7.51 ± 3.39 mmol/l and
11.02 ± 4.03 mmol/l respectively while the mean HBA1c
was 9.0 ± 2.5 %.Fasting plasma glucose less than 7.2 mmol/l was seen
in 60.2 % of patients, 44.4 % had PPG levels less than
10 mmol/l, while only 22.2 % achieved HbA1c values
less than 7 %.C peptide values
The mean fasting C-peptide was 1.44 ± 1.80 ng/ml. Fast-
ing serum C-peptide levels were classified into 3 groups
as being normal when serum C-peptide is between 0.9
to 3.0 ng/ml; as low when it is less than 0.9 ng/ml and
high when the serum C-peptide level is greater than
3.0 ng/ml. Low fasting C-peptide levels were seen in
56.7 % of the patients, 27.8 % had normal levels, while
15.6 % had elevated levels. The mean postprandial C
peptide was 4.0 ± 2.8 ng/ml. Change in C peptide was
calculated as postprandial C peptide minus fasting C
peptide. The mean change in C peptide was
2.64 ± 2.25 ng/ml.
Though the mean fasting and postprandial C peptide
levels decreased with increasing duration of diabetes, it
did not achieve statistical significance (FCP; F = 0.34,
p = 0.71, PCP; F = 0.61, p = 0.55).
The patients who were on insulin had lower fasting
and postprandial C peptide levels than those on either
oral drugs alone or diet (p = 0.001, 0.003 respectively).Beta cell response
The mean fasting beta cell responsiveness (M0) was
1.32 ± 1.71 and postprandial beta cell responsiveness
(M1) was 4.42 ± 4.62. Both fasting and postprandial beta
cell responsiveness did not correlate significantly with
the duration of diabetes (p = 0.17, 0.21 respectively).
There were also no significant correlations between M0
and age and also between M1 and age (p = 0.103, 0.082
respectively). There was however significant correlation
between M0 and HbA1c and between M1 and HbA1c
(p = 0.007 and p< 0.001).
M0 also showed significant correlations with FPG
while M1 correlated with PPG.
The patients were divided into three groups according
to their tertiles of M0 and M1 and various clinical char-
acteristics were compared across the three groups
(Tables 1 and 2).
There were significant differences in diabetes treat-
ment across the three groups. None of the patients in
the first (highest) tertile of M0 was on insulin treatment,
whereas 63.2 % of them were on diet alone. In the last
tertile of M0, there were no patients on diet alone, while
66.7 % of them were being managed on insulin.
Also, mean glycated haemoglobin levels decreased
across increasing tertiles of fasting beta cell responsive-
ness (p< 0.001) and also post prandial beta cell respon-
siveness (p = 0.002). The relationships between M0, M1
Table 1 Patients characteristics according to tertiles of
M0
Characteristic Tertile1 Tertile2 Tertile3 p
No (%) 33(36.7 %) 28(31.1 %) 29(32.2 %)
Age(years) 54.1 ± 2.0 58.7 ± 1.7 59.9 ± 2.2 0.09
Duration of diabetes(years) 8.0 ± 1.3 6.9 ± 1.5 5.6 ± 0.9 0.35
Prevalence of oral drug use (%) 20.7 24.1 33.3 0.01*
Prevalence of insulin use (%) 13.8 8 0 0.01*
BMI(kg/m2) 26.4 ± 1.0 26.5 ± 1.0 30.0 ± 1.3 0.04*
FPG(mmol/l) 9.2 ± 0.7 6.7 ± 0.5 6.4 ± 0.5 0.01*
PPG(mmol/l) 13.4 ± 0.7 9.8 ± 0.7 9.7 ± 0.7 <0.001*
GLU change(mmol/l) 4.2 ± 0.5 4.0 ± 0.4 3.9 ± 0.6 0.92
HbA1c (%) 10.9 ± 0.4 8.1 ± 0.3 8.1 ± 0.4 <0.001*
FCP(ng/ml) 0.07 ± 0.02 0.79 ± 0.1 3.5 ± 0.3 <0.001*
PCP(ng/ml) 1.65 ± 0.38 4.08 ± 0.51 6.16 ± 0.29 <0.001*
Data are expressed as means ± S.E.
BMI; body mass index, FPG; Fasting plasma glucose, PPG; postprandial glucose,
GLU change (PPG minus FPG), HbA1c; glycated haemoglobin, FCP; fasting C
peptide, PCP; postprandial C peptide.
Comparisons between means made with ANOVA and with Chi-square for
proportions.
*denotes significant values.
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Tables 1 and 2.
A comparison of the mean fasting C peptide, M0 and
M1 in patients with good glycaemic control (HbA1c
< 7 %) and those with poor glycaemic control (HbA1c ≥
7 %) showed that those with poor glycaemic control had
lower FCP, M0 and M1. However these differences were
only statistically significant for M1 (p< 0.001) but didTable 2 Patients characteristics according to tertiles of
M1
Characteristic Tertile1 Tertile2 Tertile3 p
Age (years) 57.1 ± 2.1 53.7 ± 2.2 62.2 ± 1.4 0.009
Duration of diabetes(years) 8.3 ± 1.4 6.5 ± 1.2 5.5 ± 0.9 0.25
BMI (kg/m2) 26.5 ± 1.1 28.8 ± 1.2 27.5 ± 1.0 0.35
Prevalence oral drug use (%) 17 30.7 30.7 <0.001
Prevalence insulin use (%) 15.9 3.4 2.3 <0.001
FPG(mmol/l) 8.6 ± 0.6 7.8 ± 0.6 6.0 ± 0.6 0.01
PPG (mmol/l) 12.8 ± 0.8 11.7 ± 0.6 8.5 ± 3.4 <0.001
GLU change (mmol/l) 4.3 ± 0.5 5.1 ± 0.5 2.7 ± 0.3 <0.001
HbA1c (%) 10.0 ± 2.5 9.3 ± 0.4 7.8 ± 0.4 0.002
FCP (ng/ml) 1.40 ± 0.43 1.47 ± 0.31 1.52 ± 0.25 0.97
PCP (ng/ml) 1.40 ± 0.41 4.16 ± 0.43 6.31 ± 0.25 <0.01
Data are expressed as means ± S.E.
BMI; body mass index, FPG; Fasting plasma glucose, PPG; postprandial glucose,
GLU change (PPG minus FPG), HbA1c; glycated haemoglobin, FCP; fasting C
peptide, PCP; postprandial C peptide.
Comparisons between means made with ANOVA and with Chi-square for
proportions.
*denotes significant values.not achieve statistical significance for FCP and M0.
(Table 3).
Multiple linear regression with HbA1c as a dependent
variable
In step-wise linear regression analysis using age, gender,
duration of diabetes, M0, M1 as independent variables
and HbA1c as the dependent variable, M0 and M1
emerged as significant predictors of glycated haemoglo-
bin. With M0 as a variable, the R2 value was 0.149, while
for M1, R2 was 0.207.
Discussion
This was a cross-sectional study in type2 diabetes
patients in which their beta cell function was assessed by
testing their response to a standardized meal.
Low fasting C peptide levels was common in the
patients occurring in over half of them, suggesting low
beta cell reserve. This was seen despite the relatively
short duration of diabetes in the patients (mean duration
6.7 yrs). This has been reported in similar studies dem-
onstrating low beta cell reserve in African patients with
type2 diabetes [8] .
There was a progressive decrease in both fasting and
postprandial beta cell responsiveness with increasing
duration of diabetes in the patients though unlike in
other studies[7,13], this did not reach statistical signifi-
cance. It is likely that this observation may be due to the
different rates of beta cell deterioration in the patients.
In addition, in our environment, a lot of patients with
diabetes present to the clinic very late in their illness
due to several factors such as ignorance, poor access to
health facilities and patronage of alternative medical
practitioners. Hence, a long period of hyperglycaemia
and exposure of the beta cells to excessive glucose and
the resultant glucotoxicity may result in earlier loss of
beta cell function even in those with an apparently
shorter duration of diabetes. Similarly in the study by
Bakari, fasting plasma insulin did not correlate with dur-
ation of diabetes [9].
Generally there was poor glycaemic control in majority
of the patients. In addition, M0 and M1 showed signifi-
cant correlations with HbA1c and indeed were signifi-
cant predictors of HbA1c in the regression model.
Indeed further statistical analyses showed that among
the three tertiles of both M0 and M1, HbA1c was lowestTable 3 Comparisons between patients according to
glycaemic control
Means HbA1c<7 % HbA1c> 7 % p
FC peptide (ng/ml) 1.5 1.4 0.76
M0 1.8 1.2 0.67
M1 14.4 6.5 0.17
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though even in the patients in the highest tertile of M1,
mean HbA1c was still high (7.8 %). Similarly patients
who had poor fasting and postprandial beta cell respon-
siveness and fell into the lower tertiles of M0 and M1
also had worse glycaemic control in all parameters i.e
FPG, PPG and HbA1c than those in the higher tertiles.
This was also observed in the study by Shim et al [13]
who reported that patients within the lowest tertile of
postprandial C peptide levels had higher FPG, PPG and
HbA1c levels. This suggests that the response of the beta
cell is a significant determinant of glycaemic control in
patients as also seen in studies by Shim et al [13] and
Albarrak [7], in which both M1 and M0 were predictors
of HbA1c.
However, when the patients were divided into two
groups according to their glycaemic control those with
poor glycaemic control had lower FCP, M0 and M1 than
those with good glycaemic control though these differ-
ences were more significant for M1. Hence these differ-
ences were more marked with postprandial beta cell
responsiveness which has been shown in other studies to
be more predictive of glycaemic control than the fasting
beta cell responsiveness [13].
Most of the patients who were on insulin were seen in
the lowest tertiles of M1 and M0, and none of the
patients in the highest tertiles was on insulin treatment.
This is as expected as those on insulin are likely those
patients who had been poorly controlled on oral agents,
suggesting poor beta cell function. Similarly, Oli et al
[11] reported that lower glucagon stimulated C peptide
levels predicted sulphonyl urea failure and need for insu-
lin treatment in Nigerian patients with type2 diabetes.
It was observed that a lot of the patients with poor
beta cell function (lowest tertiles of M0 and M1) were
managed with oral agents alone. Majority of them were
on sulphonylureas which act by stimulating endogenous
insulin release from the beta cells. Despite this, they still
had poor beta cell stimulation from the meal and their
drugs. It is possible that insulin treatment in this group
would have resulted in better indices of glycaemic con-
trol in them.. The use of oral drugs in the patients with
relatively poor beta cell responsiveness may have con-
tributed to the high degree of poor glycaemic control.
One of the limitations of this study was the inability to
collect multiple blood samples for the analysis of C pep-
tide within the two hour sampling period, hence the
need to use a simplified method for estimation of beta
cell responsiveness. Though this equation has been used
in a previous study [13], it is not known if more detailed
sampling and C peptide modeling would yield similar
results. In addition, antibody testing was not done to
clearly differentiate between type1 and type2 diabetic
patients and this may have affected the C peptidemeasurements as a few patients may have been improp-
erly classified as having type2 diabetes.
Conclusion
This study has shown that quite a significant proportion
of our patients have low C peptide levels with poor beta
cell response to meal stimulation. This suggests a rapid
decline in beta cell function in them and that beta cell
failure is a predominant feature in our patients with
type2 diabetes. Late presentation for treatment with a
long level of exposure of the beta cells to glucose from
prolonged hyperglycaemia is likely to be a significant
contributor to this decline in beta cell function. Fasting
and postprandial beta cell responsiveness were signifi-
cant determinants of blood glucose and glycated haemo-
globin levels.
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